Genelux Boosts Next-Generation Cancer Treatment: Secures $10.5M to Accelerate Oncolytic Immunotherapy Advancements

Genelux Corporation (NASDAQ: GNLX), a groundbreaking late clinical-stage biotechnology company, is proud to announce that it has raised $10,500,000 in its latest funding round. This significant infusion of capital is set to accelerate Genelux’s ambitious research and development efforts aimed at combating aggressive, difficult-to-treat solid tumors. The company’s innovative ChoiceTM Discovery Platform, which has already produced over 500 versions of the vaccinia virus, underpins the development of next-generation oncolytic immunotherapies that harness the full complement of tumor neo-antigens, thereby stimulating a personalized immune response for patients. A major focus of this funding is the continued advancement of Olvi-Vec, Genelux’s lead product candidate, currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). In addition to its work in ovarian cancer, Olvi-Vec is being actively developed for use in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer, underscoring the company’s commitment to diversifying and expanding its clinical pipeline. The latest funding will bolster ongoing clinical trials, enhance the company’s manufacturing capabilities, and support efforts to bring these innovative therapies one step closer to patients in need. “This investment not only validates our scientific approach but also propels us toward our goal of delivering transformative cancer treatments,” said a Genelux executive. For more information about Genelux’s investigational products and clinical trials, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux.